A Double Blind Placebo Controlled Study to Assess the Efficacy on Joint Damage in RA Patients

Inclusion Criteria: * Clinically diagnosed as rheumatoid arthritis by the revised ACR criteria * Those who have been treated with an adequate stable dose of either methotrexate, salazosulfapyridine or bucillamine * Those who have at least one erosion on X-ray of hands, wrists or feet Exclusion Criteria: * Those who have been treated with any biologic drugs or leflunomide * Those who meet Class 4 with the Steinbrocker functional classification